The Latest Breaking News from Macular Degeneration

Judi Dench says sight loss means she can no longer perform but she is still ‘besotted by’ Shakespeare’s sonnets

Age-related macular degeneration has also left actor, 91, unable to read or recognise faces any more

The Guardian - UK · Oct 22

Dame Judi Dench Briefly Responds to James Bond Casting Question Amid Heartbreaking Health Update

Judi Dench reportedly answered 'No' when asked about the next James Bond, as the 91-year-old actor discussed how worsening age-related macular degeneration has affected her career.

International Business Times UK · Oct 22

Dame Judi Dench says worsening eye condition means she 'can no longer act' in heartbreaking health update

The actress, 91, says she can no longer perform or read due to age-related macular degeneration (AMD)

Evening Standard · Oct 22

Scientists Discovered How Babies Develop Sharp Central Vision Before Birth, and Vitamin A Plays a Bigger Role Than Anyone Knew

Johns Hopkins researchers found blue cone cells transform into red and green cones via Vitamin A and thyroid hormones during fetal development, overturning how scientists understood sharp vision.

Medical Daily · Jul 13

6 Nutrients Your Eyes Need for Better Vision That Most Indians Are Missing From Their Diet

Lutein: The filter your retina is running low onLutein is a carotenoid that deposits directly into the macula, the central part of the retina responsible for sharp, detailed vision. It acts as a biological filter against blue light and oxidative stress. The average Indian diet delivers roughly 1 to 2…

Times Life · Jul 8

Our eyes age too: Here’s how to reduce the risks of four common eye conditions

As an optometrist, I see how aging affects my patients every day. Their eyes are no exception. Losing their vision, and consequently, their independence, is one of the greatest fears older people have. Those who lose their vision are severely affected by it psychologically.

The Conversation · Jun 16

Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10

SHENZHEN, China, June 4, 2026 /PRNewswire/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), a wholly-owned subsidiary of Kexing Biopharm. Designed to treat neovascular…

AAP · Jun 4

EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears

Eyepoint Pharmaceuticals (NASDAQ:EYPT) executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-1901, beginning in August, with a second pivotal trial expected to follow about two months later.

MarketBeat · May 26

How looking through static can help people with a common degenerative disease see better

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness among ageing people globally. Around one in seven Australians over the age of 50 have some signs of AMD.

The Conversation · May 17

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

4D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage development for wet age-related macular degeneration and prepares to begin a Phase 3 trial in diabetic m

MarketBeat · May 17